N90% of uLMS diagnosed in Japan had an appropriate pathological diagnosis. • Advanced clinical stage, high serum LDH level, and menopausal status are poor prognostic factors in uLMS. • Adjuvant chemotherapy improved PFS and OS in stage I uLMS. a b s t r a c t
Objective. Uterine leiomyosarcoma (uLMS) is a rare gynecologic malignancy for which the currently available treatments do not consistently provide long-term disease control. This study aimed to reveal the current clinical status of uLMS to support future clinical trials.
Methods. This study enrolled patients with uLMS treated at 53 Japanese institutions from 2000 to 2012. Central pathological review (CPR) was performed. All cases were confirmed by CPR, and epidemiological features, treatment, and prognosis were analyzed statistically.
Results. A total of 307 patients were enrolled. A diagnosis of uLMS was confirmed in 266 patients (86.6%) of patients after CPR, of whom data for 259 were analyzed. Of these, 186 (71.8%) patients underwent complete gross resection as primary therapy. Ninety-eight patients received no additional adjuvant therapy, while docetaxel and gemcitabine was the most frequent regimen among 155 patients treated with adjuvant chemotherapy. In all cases, the median overall survival (OS) was 44.2 months. Multivariate analyses of prognostic factors in all cases identified stage III and IV disease, high serum lactate dehydrogenase level, and menopausal status as poor prognostic factors. However, in stage I cases, high serum lactate dehydrogenase level and no adjuvant treatment were identified as poor prognostic factors. The 5-year OS of patients with stage I uLMS treated with adjuvant chemotherapy was significantly better than that of those without adjuvant treatment (67.8% vs 46.7%, P = 0.0461).
Conclusions. Despite complete removal of the primary lesion, the clinical course of patients with uLMS was poor
Introduction
Uterine leiomyosarcoma (uLMS) is an aggressive malignant tumor with a poor prognosis, regardless of stage. uLMS arises from the uterine smooth muscle, and accounts for 3%-7% of all uterine malignancies and approximately 1% of all female genital tract cancers [1] . Most patients with uLMS have uterus-confined disease presenting at clinical stage I [2] ; however, many cases are only diagnosed after hysterectomy [3] .
The outcomes of uLMS are poor, with a reported 5-year disease-specific survival rate of 66% [2] and 5-year overall survival (OS) rates for stage I, II, III, and IV disease of 55.4%, 32.6%, 24.6%, and 13.1%, respectively [4] .
Regarding treatment, surgical excision remains the mainstay of management for uLMS. Chemotherapy has also been shown to increase survival among women with metastatic leiomyosarcoma [4] , though the optimal use of adjuvant therapies in patients with non-metastatic leiomyosarcoma remains unclear, or has shown poor efficacy [5] . Despite complete, intact resection, the risk of recurrence approaches 50%-70% in patients with stage I uterus-limited LMS [1] , and approximately 40% in patients with extra-uLMS [6] . Additional postoperative chemotherapy may be expected to benefit patients with stage I disease; however, its utility currently remains unproven. The rarity of uterine sarcomas, and the previous inclusion of patients with other pathologies (i.e. carcinosarcoma), different dosing regimens, and radiation therapy have made the direct comparison of agents almost impossible [7] .
We therefore conducted a retrospective cohort study to evaluate the current status and prognostic factors of uLMS, to facilitate future clinical trials and identify potential ways of improving the long-term prognosis in patients with uLMS in Japan.
Methods
This multi-institutional retrospective cohort study included patients with uLMS treated at 53 Japanese institutions comprising the Japan Gynecologic Oncology Group (JGOG) between 2000 and 2012 (S1). The inclusion criteria were patients who underwent surgery as primary treatment and who had a pathological diagnosis of uLMS at the respective institution. In all cases, histopathological slides of the primary lesions were examined by a central pathological review (CPR) board to confirm the diagnosis of uLMS. Clinical data were obtained from medical records.
This study was approved by the Institutional Review Board of the National Hospital Organization Shikoku Cancer Center and by each participating institution. The need for informed consent was waived because of the retrospective nature of the study.
1) CPR board
The CPR board comprised six pathologists who specialized in gynecological pathology. Three teams of two pathologists each classified the cases as "LMS, eligible," "smooth muscle tumor, benign or insufficient for malignancy," "non-leiomyomatous neoplasm," or "pending judgment."
If no consensus was reached between two pathologists or if one of them required further discussion, the specimens were re-examined by all six pathologists and the diagnosis was revised accordingly.
2) Statistical methods
Progression-free survival (PFS) was defined as the time from the date of primary treatment to the date of either disease recurrence or progression from any cause or to the last follow-up date, whichever occurred first. Cutoff values of CA125 and LDH were determined based on a ROC curve. The ROC curve was estimated using R's survival ROC package (R version 3.3.2, R Foundation for statistical Computing, Vienna, Austria). OS was defined as the time from the date of primary treatment to the date of either death or last follow-up. PFS and OS curves were estimated using the Kaplan-Meier method and survival estimates were compared using the log-rank test. Univariate and multivariate Cox regression analyses of PFS and OS were performed and the prognostic factors were further examined using stepwise variable selection analyses (α = 0.05), and the hazard ratios (HRs) and 95% confidence intervals (CI) were estimated. A two-sided P value b0.05 was considered statistically significant. Statistical analyses were performed using Stata version 14.2 (StataCorp, College Station, TX, USA).
Results

1) CPR
A total of 307 patients were registered in this study, of whom 282 (91.9%) were diagnosed with LMS after CPR. Twenty-five cases were not diagnosed as LMS, including nine diagnosed as benign leiomyoma or smooth muscle tumor, benign or insufficient for malignancy, eight as non-leiomyomatous neoplasm, and eight as pending judgment due to insufficient specimens or clinical information. The eight cases of non-leiomyomatous neoplasm included two cases of undifferentiated sarcoma, two adenosarcomas, and one case each of endometrial stromal sarcoma, uterine tumor resembling ovarian sex cord tumor, malignant mesothelioma, and metastatic uterine tumor (metastasis from renal cell carcinoma into leiomyoma with bizarre nuclei).
Among the 282 cases of LMS, 16 were diagnosed as of extra-uterine origin or with insufficient findings to determine a uterine origin. A total of 266 cases were finally pathologically confirmed as uLMS.
2) Clinical data analysis
Among the 266 cases of uLMS diagnosed by CPR, seven had inadequate clinical data, and 259 uLMS patients were therefore analyzed for clinical features and prognosis (S2). The median age of all patients was 54 years (range: 21-83), and the clinical stage was stage I in 159 (61%), stage II in 19 (7%), stage III in 21 (8%), and stage IV in 58 (22%) patients. The median preoperative serum level of CA-125 was 17.3 U/ ml (range: 2.2-944), and lactate dehydrogenase (LDH) was 274 IU/l (range: 101-3569). The median gross tumor size was 12 cm (range: 3-36). Macroscopic necrosis and hemorrhage at the cut surface of the tumor were recognized in 73.4% (190/259) and 53.3% (138/259), respectively (Table 1) .
3) Treatment
A total of 167 of the 259 patients (64.5%) underwent hysterectomy and oophorectomy, and 65 (25.1%) received hysterectomy, oophorectomy, and/or lymphadenectomy, and/or resection of extra-uterine lesions. Thirty-three patients (12.7%) underwent lymphadenectomy. Among patients with stage I uLMS, there was no prognostic difference between patients with and without lymphadenectomy in terms of either disease-free survival (DFS) (P = 0.722) or OS (P = 0.349) All lesions were completely removed in 186 patients (71.8%). Regarding the preoperative diagnosis of stage I disease, 26 cases were diagnosed as uLMS, 10 cases as other malignant tumors, 80 as suspected uLMS, and 43 as leiomyoma. Three patients with stage I uLMS, diagnosed preoperatively as leiomyoma, underwent direct tumor resection including myomectomy, laparoscopic morcellation, and transcervical tumor resection. Although hysterectomy was performed immediately after diagnosis, two of three cases relapsed. A total of 159 patients received adjuvant treatment, including 151 who received chemotherapy, four who received both chemotherapy and radiotherapy, and four who received adjuvant radiotherapy ( Table 2) .
Regarding the chemotherapy regimen, docetaxel and gemcitabine therapy was the most frequent regimen (41.9%, 65/155), followed by ifosfamide, doxorubicin, and cisplatin regimen (20.6%, 32/155) (S3).
4) Outcomes and prognostic factors
The median follow-up period was 55.6 months (0.99-169.2). Relapse was observed in 130 patients, with recurrence in lung in 83 cases, abdominal cavity in 51, bone in 16, liver in 11, subcutaneous tissues in nine, lymph nodes in seven, central nerve or spinal cord in three, and the pancreas in one case. Regarding the site of recurrence of stage I uLMS, lung was the most frequent site, followed by the abdominal cavity, bone, and liver (S4). After recurrence, seven patients who underwent surgical resection of lung metastases remained alive without disease.
The Cutoff levels of CA125 and LDH in all cases provided by the ROC curve were 23 and 243, respectively ( Fig. 1-a) . Univariate analysis of prognostic factors in all cases identified poor performance status, high serum LDH, extra-uterine lesions, distant metastasis, large tumor size, presence of necrosis, advanced clinical stage, and presence of residual tumor as factors related to a poor prognosis. Multivariate analysis identified stage III-IV disease, high serum LDH, and menopausal condition as factors significantly associated with shorter median PFS and OS periods ( Table 3) .
Cutoff levels of CA125 and LDH in stage I cases provided by the ROC curve were 25 and 191, respectively ( Fig. 1-b ). Univariate analysis of prognostic factors in patients with stage I disease showed that poor performance status, high serum LDH, large tumor size, presence of necrosis, and no adjuvant therapy were related to a poor prognosis, while multivariate analysis identified high serum LDH and no adjuvant therapy as factors significantly associated with shorter median DFS and OS periods ( Table 4 ).
The 5-year OS among patients with stage I uLMS who received adjuvant chemotherapy was 67.8% compared with 46.7% in those without adjuvant treatment. Adjuvant chemotherapy was associated with significantly better OS compared with observation in patients with stage I uLMS (P = 0.0461) (Fig. 2 ).
Discussion
It is difficult to conduct prospective clinical trials in patients with uLMS because of the rarity of the condition. The current retrospective cohort study aimed to investigate the current clinical status of this rare tumor and to explore the possibilities for future prospective clinical trials. This study examined the current status of uLMS in Japan in terms of its diagnosis, treatment, and outcomes. As reported previously [4] , most cases (62%, 159/259) of uLMS were diagnosed as stage I, followed by stage IV. The frequency of each clinical stage in the current study was in accord with a recent gynecologic tumor treatment report from the Japan Society of Obstetrics and Gynecology, indicating that the current sample was representative. Furthermore, the median age in this study was 54 years, which was similar to that reported by Seagle et al. [4] . In contrast however, the current median tumor size was 12 cm (3-36), which was slightly larger than in this previous report [4] .
Despite the use of comprehensive imaging modalities, such as computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography, only 16.4% (26/159) of patients in the present study received a diagnosis of uLMS before surgery, and a pathological diagnosis of uLMS was usually made after hysterectomy [3] . The Stanford criteria [8] are commonly used for the histologic diagnosis of uLMS, which is distinguished from leiomyoma by a high cell concentration, marked nuclear pleomorphism, N15 mitotic counts per 10 high-power fields, and presence of coagulative necrosis. However, expert review by a pathologist who specializes in gynecologic pathology or soft tissue tumors is recommended to distinguish it from atypical leiomyoma, smooth muscle tumor of uncertain malignant potential (STUMP), and certain other lesions [3] . In the current study, about 90% of the pathological diagnoses at each facility were identified as LMS by CPR. The low frequency of atypical leiomyomas and STUMP, and the fact that expert review is requested at each facility in Japan, may contribute to the high probability of an LMS diagnosis. This suggests that patients with a uLMS diagnosis at most institutions in Japan would be suitable for a prospective clinical trial. However, about 3% of benign or borderline tumors have been treated as LMS. Malignant tumors wrongly diagnosed as LMS include undifferentiated sarcoma, adenosarcoma, endometrial stromal sarcoma, uterine tumor resembling ovarian sex cord tumor, malignant mesothelioma, and metastatic uterine tumor from renal cell carcinoma, and it is therefore necessary to exercise care in differentiating between uLMS and these tumors.
The current cohort of Japanese patients with uLMS had a median PFS of 18.2 months and a median OS of 44.2 months, respectively. Because we aimed to analyze cases in which uLMS was diagnosed in the removed primary lesion, we excluded advanced cases treated with chemotherapy alone, and cases diagnosed only from metastasis or biopsy. The prognoses of patients not eligible for surgery and patients treated with best supportive care are therefore expected to be worse than those of patients analyzed in the current study. The 5-year OS in relation to clinical stage was stage I 57.1%, stage II 44.6%, stage III 20.4%, and stage IV 23.2%. The prognosis for stage I disease was similar to that in the National Cancer Database reported by Seagle et al. [4] . In patients with stage I uLMS, the primary lesion can be removed completely by hysterectomy. In the present study, 77.4% (123/159) of patients with stage I disease underwent hysterectomy for leiomyoma or suspected uLMS. However, there was no prognostic difference between patients diagnosed with uLMS and those diagnosed with leiomyoma or suspected uLMS. Myomectomy or morcellation has been associated with a higher risk of recurrence [9, 10] . If laparoscopic morcellation was performed to unexpected uLMS, intra-peritoneal recurrence would be higher [10] ; however, only three patients with stage I disease in the current cohort underwent such surgery. Recent reports suggested that there was no disadvantage of ovarian preservation [4, 11] or lack of lymph node dissection [4, 12] in terms of treatment results. This suggests that if hysterectomy is performed reliably in stage I, further surgical procedures may have little impact on patient prognosis. Chemotherapy is selected as postoperative adjuvant treatment in many patients in Japan, though the chemotherapy regimens differ among institutions. Gemcitabine plus docetaxel therapy was most common regimen in Japan; however, the Japanese Health Insurance Act does not permit prophylactic administration of granulocyte-colony stimulating factor, and modified gemcitabine plus docetaxel [13] is therefore administered in many institutions.
Clinical stage, high serum LDH, and postoperative adjuvant therapy were identified as prognostic factors in this study. Although LDH is measured preoperatively to distinguish uLMS from benign leiomyoma, its sensitivity is low [14] and it is therefore not useful as a single predictive biomarker. However, LDH has been studied in combination with imaging tests such as MRI and ultrasound, and in combination with factors such as alkaline phosphatase and C-reactive protein [15] . A high serum level of LDH was identified as a factor significantly associated with a poor prognosis in the current study.
Chemotherapy is considered to be clinically valuable in patients with advanced or recurrent uLMS [16] [17] [18] [19] [20] . In clinical practice, chemotherapy was reported to increase the survival of women with metastatic LMS [4] . However, the significance of postoperative adjuvant therapy for stage I uLMS remains unclear. Littell et al. recently reported that there was insufficient evidence to support the routine administration of four to six cycles of gemcitabine-docetaxel chemotherapy as adjuvant therapy for stage I uLMS [21] . Bogani et al. made meta-analysis about the efficacy of adjuvant chemotherapy in improving disease-free survival in patients affected by early stage uterine leiomyosarcoma. They analyzed 360 patients of five papers who were treated 1973 to 2011, and they concluded that the role of adjuvant chemotherapy remains unclear in early stage uterine leiomyosarcoma and further innovative therapeutic strategies have to be tested [22] . In addition, GOG 0277, a randomized phase III superiority trial of gemcitabine plus docetaxel followed by doxorubicin versus observation in women with uterus-limited, highgrade LMS, showed no superior survival outcomes in patients with adjuvant chemotherapy [23] . However, although GOG 0277 was an international trial, poor accrual meant that the sample size precluded robust statistical comparison. Given that stage I patients account for at least 50% of cases of uLMS, it is necessary to prevent recurrence in these patients to improve the overall prognosis of uLMS.
This study had some limitations, including bias associated with treatment selection by some clinicians. Detailed prognostic exploration of stage I disease could not be performed due to the bias of stage Ia and Ib distribution. Chemotherapy regimens were also non-standardized as the criteria for patients undergoing chemotherapy are different at each institution. Furthermore, this study focused on Japanese women, and the results may therefore only reflect the current situation at medical institutions in Japan. However, this study used a CPR board to select appropriate cases, and the clinical conclusions of this study were thus more specific to uLMS. In addition, our data did not originate from a socalled cancer registry, and we could therefore analyze histopathological and other clinical and laboratory data, including relapse information. In conclusion, this study clarified the current clinical status of uLMS, with the ultimate aim of facilitating future clinical trials and improving the prognosis of uLMS. The diagnostic concordance rate with the CPR board was 86.6%, which was higher than expected, which supports the implementation of a uLMS trial.
The prognosis of uLMS was poor, with a median PFS of 18.2 months and median OS of 44.2 months. The Kaplan-Meier PFS curve showed that many recurrences occurred within 24 months. The median OS was only 67.8 months even in stage I patients in whom the disease lesion had been completely removed by surgery. Furthermore, the pattern of recurrence often involved distant metastases in the lung, bone, liver, or other tissues.
This study identified advanced clinical stage, high serum LDH level, and menopausal status as poor prognostic factors, and adjuvant chemotherapy improved OS even in patients with stage I disease. Although the GOG 0277 trial did not prove superiority of adjuvant chemotherapy in terms of OS [23] and recurrence-free survival in patients who remained disease free according to CT or MRI, there is a need to identify high-risk patients using biomarkers such as high LDH, p53, and Ki-67, and for the development of more effective chemotherapies. We consider that implementing effective adjuvant therapy in patients with stage I uLMS at high risk of recurrence, which accounts for half of all cases, may improve the overall prognosis of uLMS.
